Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...

She could go to a med-spa, but that would cost about $1,000 a month, still too much for the new therapist ... it became the ...

European Union antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ acquisition of contract drug ...

Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...

Read More: No One Knows How to Talk About Weight Loss ... are approved) and obesity (the target of Wegovy and Zepbound). They ...

The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections (uUTIs). Orlynvah (sulopenem etzadroxil and probenecid) is a broad-spectrum ...

“Orlynvah has the potential to be an important treatment option for those who need it,” she said in a news release from Iterum Therapeutics, the drug’s maker. The FDA approved Orlynvah based ...

Both Ozempic and Mounjaro are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes, but some doctors ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

Share on Pinterest A drug that has already gained FDA approval for the treatment of ulcerative colitis is also effective in the treatment of Crohn’s, new data suggest. Brothers91/Getty Images ...